BJBjörn Johansson

Björn Johansson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Björn Johansson has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • ESDR413 - Role of calcitonin gene-related peptide in atopic dermatitis

    by Saly Abdelhadi, Klas Nordlind, Björn Johansson, Mikael Holst, Louise Lönndahl

    Atopic dermatitis (AD) is an often severely pruritic chronic inflammatory disease often worsened by psychological stress. Calcitonin gene-related | POSTER

  • Open Access

    Challenges and Controversies in COVID-19: Masking the General Population may Attenuate This Pandemic's Outbreak

    by Björn Johansson

    SARS-CoV-2, the virus that causes COVID-19, spreads i. a., by respiratory droplets. The use of masks in preventing spread is controversial; masks are considered useless by many, while being mandated in some locations. Here, the effect of masking the general population on a COVID-19-like epidemic is estimated by computer simulation using three separate types of software. The main questions are whether mask use by the general population can limit the spread of SARS-CoV-2 in a country and how to identify opportunities when mask use is cost-effective and safe. To address these questions, the protective effects of different types of masks, the side-effects of masks, and avenues for improvements of masks and masking are addressed. Main results: (i) Any type of mask, even simple home-made ones, may be of value, even if the protective effect of each mask (here dubbed “one mask-protection”) is low. Strict adherence to mask use does not appear to be critical but increasing one mask-protection to >50% was found to be advantageous. (ii) Masks do seem to reduce the number of new cases even if introduced at a late stage in an epidemic, but early implementation helps reduce the cumulative and total number of cases. (iii) The simulations suggest that it might be possible to eliminate a COVID-19 outbreak by widespread mask use during a limited period. There is a brief discussion of why the reported effect size of masking varies widely, and is expected to do so, because of different filtration abilities of different masks, differences in compliance and fitting, other routes of transmission, pre-existing immunity, and because a system of interconnected, disease-prone individuals has non-linear properties. A software solution to visualize infection spread is presented. The results from these simulations are encouraging, but do not necessarily represent the real-life situation, so it is suggested that clinical trials of masks are now carried out while continuously monitoring effects and side-effects. As mask use is not without risks and costs, it is suggested that governments and scientists have an important role in advising the public about the sensible use of masks.


  • Open Access

    Editorial: Pharmacology of BPSD (Behavioral and Psychological Symptoms of Dementia)

    by Lydia Giménez-Llort, Björn Johansson

    Editorial: Pharmacology of BPSD (Behavioral and Psychological Symptoms of Dementia)


  • Effects of Naltrexone and Acamprosate on Alcohol-Induced NGFI-A Expression in Mouse Brain

    by Jeanette Lindholm, Marc Guitart-Masip, Homa Hassankhali, Sara Landgren, Camille Nicoleau, Lydia Giménez-Llort, Lars Terenius, Sven Ove Ögren, Björn Johansson

    In search for the substrate of naltrexone and acamprosate action on alcohol craving, we investigated the effects of ethanol alone and combined with naltrexone or acamprosate on expression of nerve growth factor-inducible clone A (NGFI-A; zif268). In Experiments 1 and 3, alcohol (2 g/kg) alone or in combination with naltrexone (15 mg/kg) or acamprosate (300 mg/kg) was injected intraperitoneally into mice. In Experiment 2, treatment was nor-BNI (0.5 mg/kg) to investigate whether the effect of naltrexone involved blockade of κ-opioid receptors. Both ethanol and naltrexone alone induced NGFI-A in the central amygdala, but not in several other areas; these effects were additive. However, acamprosate alone or in combination with ethanol had no effect on NGFI-A mRNA, while nor-BNI induced NGFI-A mRNA in the basolateral amygdala. The central amygdala appears to be an important target of both alcohol and naltrexone. Acamprosate may not share the site of action with naltrexone despite being used for the same therapeutic purpose.